Table 1 Adjuvant nanomedicine approved or undergoing clinical trials for lung cancer therapy
From: Nanomedicine-based adjuvant therapy: a promising solution for lung cancer
Nanomedicine | Formulation | Combination | Application | Phase of study | Current status | Institution | ClinicalTrials.gov Identifier | |
|---|---|---|---|---|---|---|---|---|
Abraxane (Nab-paclitaxel) | Albumin-bound PTX | / | NSCLC | FDA approved | / | Abraxis BioScience | / | |
Genexol-PM | PTX-loaded micelle (PEG-PLGA) | / | NSCLC | Approved in Korea | / | Samyang Holdings Biopharmaceuticals | / | |
Lipusu | PTX liposome | Gemcitabine; Cisplatin | Advanced Squamous NSCLC | Phase IV | Unknown | Nanjing Luye Sike Pharmaceutical Co. | NCT02996214 | |
CT-2103 (Xyotax) | Polyglutamate PTX | Pemetrexed | Advanced NSCLC | Phase II | Completed | Dartmouth-Hitchcock Medical Center | NCT00487669 | |
NC-6004 | Nanoparticle cisplatin | Gemcitabine | NSCLC | Phase I/II | Completed | NanoCarrier Co. | NCT02240238 | |
Doxil | Pegylated liposomal doxorubicin | Topotecan | SCLC | Phase I | Completed | Christiana Care Health Services | NCT00252889 | |
ATRC-101; Pembrolizumab | NSCLC | Phase I | Recruiting | Atreca, Inc. | NCT04244552 | |||
BIND-014 | Docetaxel nanoparticles | / | NSCLC | Phase II | Completed | BIND Therapeutics | NCT01792479 | |
/ | KRAS Positive or Squamous NSCLC | Phase II | Completed | BIND Therapeutics | NCT02283320 | |||
CRLX101 (NLG207) | Camptothecin conjugated to a cyclodextrin-based polymer | / | Advanced NSCLC | Phase II | Completed | Lumos Pharma (NewLink Genetics Corporation) | NCT01380769 | |
NKTR-102 | Pegylated irinotecan | / | Relapsed SCLC | Phase II | Completed | Roswell Park Cancer Institute | NCT01876446 | |
/ | Metastatic and Recurrent NSCLC | Phase II | Completed | Abramson Cancer Center of the University of Pennsylvania | NCT01773109 | |||
Onivyde | Irinotecan liposome | Topotecan | SCLC | Phase II/III | Active, not recruiting | Ipsen | NCT03088813 | |
Topotecan liposome | Topotecan liposome | / | Advanced SCLC | Phase I | Recruiting | Fujifilm Pharmaceuticals U.S.A., Inc. | NCT04047251 | |
/ | Advanced SCLC | Phase I | Completed | Spectrum Pharmacerticals, Inc | NCT00765973 | |||
OSI-211 (NX-211) | Liposomal Lurtotecan | / | Recurrent SCLC | Phase II | Completed | Astellas Pharma Inc | NCT00046787 | |
Cisplatin | Advanced or Metastatic lung cancer | Phase I | Completed | Canadian Cancer Trials Group | NCT00006036 | |||